ArticleMedicine2026
Exploring the potential role of ADIPOR2 related to immune microenvironment and metabolism dysfunction in non-alcoholic steatohepatitis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nonalcoholic steatohepatitis (NASH) is a metabolic disorder, and immune-mediated inflammation plays an important role in the progression of the disease. AdipoR2, encoded by ADIPOR2, is closely involved in the pathogenesis of NASH through adiponectin signaling. However, the relationship between ADIPOR2 and the immune microenvironment and metabolic dysfunction in NASH patients remains unexplored. NASH datasets were collected from the public database. ADIPOR2 expression level and its diagnostic value were explored. Then, the relationships among ADIPOR2, the immune microenvironment, and metabolic dysfunction were investigated. ADIPOR2-related genes were identified, a regulatory network was established, and drug sensitivity analysis was conducted. In addition, ADIPOR2 was also verified in clinical samples. ADIPOR2 expression was significantly increased in NASH patients compared to healthy controls and shows better diagnostic value. Immune infiltration analysis found that T cells CD4 memory resting and dendritic cells resting were significantly different in healthy controls versus NASH patients, and ADIPOR2-low versus ADIPOR2-high expression groups. Gene set enrichment analysis and gene set variation analysis showed that metabolism-related pathways (such as HALLMARK_CHOLESTEROL_HOMEOSTASIS, HALLMARK_FATTY_ACID_METABOLISM, and HALLMARK_PEROXISOME) were significantly upregulated in NASH and ADIPOR2-high expression groups. Correlation analysis revealed that ADIPOR2 expression was closely linked to these immune cells and metabolism-related pathways. Then, 16 ADIPOR2-related genes were identified, and the miRNAs-ADIPOR2-TFs regulatory network was constructed. In addition, patients in the ADIPOR2-low expression group showed higher sensitivity to drugs. ADIPOR2 may be a potential diagnostic target and could be related to immune cells and metabolic dysfunction in NASH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.